|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-2.39/-1.55
|
企业价值
315.32M
|
资产负债 |
每股账面净值
-1.78
|
现金流量 |
现金流量率
--
|
损益表 |
收益
--
|
每股收益
1.27
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/12/24 13:16 EST
同行比较之报价最少15分钟延迟
业务概览
|
|||
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212. |